Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Krane Funds Advisors LLC

Krane Funds Advisors LLC lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 5,532 shares of the biopharmaceutical company’s stock after selling 575 shares during the quarter. Krane Funds Advisors LLC’s holdings in Gilead Sciences were worth $511,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. HHM Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership acquired a new stake in Gilead Sciences in the 4th quarter worth about $28,000. Decker Retirement Planning Inc. purchased a new stake in Gilead Sciences during the 4th quarter worth approximately $29,000. Crews Bank & Trust acquired a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $31,000. Finally, Stephens Consulting LLC lifted its position in shares of Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 260 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the company’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at $12,626,253.06. This represents a 52.26 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders sold 302,785 shares of company stock valued at $30,503,250. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Stock Down 4.6 %

Shares of NASDAQ:GILD opened at $107.25 on Monday. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The firm has a 50 day simple moving average of $107.30 and a 200-day simple moving average of $95.98. The company has a market capitalization of $133.54 billion, a PE ratio of 289.86, a P/E/G ratio of 0.71 and a beta of 0.32. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were paid a $0.79 dividend. The ex-dividend date of this dividend was Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.95%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is currently 854.05%.

Analyst Ratings Changes

Several research analysts recently commented on the company. Morgan Stanley increased their price objective on Gilead Sciences from $123.00 to $130.00 and gave the company an “overweight” rating in a research note on Tuesday, March 11th. JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, March 27th. The Goldman Sachs Group upped their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a research report on Thursday, February 13th. Finally, Oppenheimer lifted their price objective on Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a research note on Tuesday, March 4th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $105.12.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.